Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)
Details : CIBINQO (abrocitinib) is an oral inhibitor of Janus kinase 1. Inhibition of JAK1 is thought to modulate multiple cytokines involved in pathophysiology of AD, including interleukin (IL)-4, IL-13, IL-31, IL-22, and thymic stromal lymphopoietin (TSLP).
Product Name : Cibinqo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 02, 2023
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ritlecitinib
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Litfulo (ritlecitinib) is an inhibitor of JAK3 and the TEC family kinases. Inhibition of JAK3 and TEC kinase family members by LITFULO may block signaling of cytokines and cytolytic activity of T cells, which is implicated in the pathogenesis of alopecia...
Product Name : Litfulo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 19, 2023
Lead Product(s) : Ritlecitinib
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ritlecitinib
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pfizer Receives Positive CHMP Opinion for Alopecia Areata Treatment
Details : LITFULO (ritlecitinib) is an inhibitor of JAK3 and the TEC family kinases. Inhibition of JAK3 and TEC kinase family members by LITFULO may block signaling of cytokines and cytolytic activity of T cells, which is implicated in the pathogenesis of alopecia...
Product Name : Litfulo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 21, 2023
Lead Product(s) : Ritlecitinib
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ritlecitinib
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
US FDA Approves Pfizer's Hair Loss Drug
Details : LITFULO (ritlecitinib) is an inhibitor of JAK3 and the TEC family kinases. Inhibition of JAK3 and TEC kinase family members by LITFULO may block signaling of cytokines and cytolytic activity of T cells, which is implicated in the pathogenesis of alopecia...
Product Name : Litfulo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 23, 2023
Lead Product(s) : Ritlecitinib
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ritlecitinib
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
UK Regulator Approves Pfizer's Hair Loss Drug
Details : Litfulo (ritlecitinib) is an inhibitor of JAK3 and the TEC family kinases, which may help in blocking the signaling of cytokines and cytolytic activity of T cells, which is implicated in the pathogenesis of alopecia areata.
Product Name : Litfulo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 11, 2023
Lead Product(s) : Ritlecitinib
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ritlecitinib
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PF-06651600 (ritlecitinib) is an investigational oral once daily treatment that is the first in a new class of oral highly selective kinase inhibitors that is a dual inhibitor of the TEC family of tyrosine kinases and of Janus kinase 3 (JAK3).
Product Name : Litfulo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 09, 2022
Lead Product(s) : Ritlecitinib
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FDA approval for Cibinqo (Abrocitinib) JAK1 inhibitor, was based on the results of five clinical trials from a large-scale clinical trial program of more than 1,600 patients for the treatment of adults living with refractory, moderate-to-severe atopic de...
Product Name : Cibinqo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 14, 2022
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Abrocitinib is oral small molecule that selectively inhibits JAK1. CHMP adopted positive opinion for marketing authorization to treat moderate to severe atopic dermatitis (AD), and CHMP also recommends XELJANZ® (tofacitinib) approval for treatment of a...
Product Name : Cibinqo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 15, 2021
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The approval of Cibinqo (Abrocitinib) was based on the results of clinical studies for the treatment of moderate-to-severe atopic dermatitis (AD) in adults demonstrated meaningful improvements across measures of symptom relief.
Product Name : Cibinqo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 12, 2021
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pfizer Inc today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Great Britain marketing authorization for CIBINQO® (abrocitinib).
Product Name : Cibinqo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 09, 2021
Lead Product(s) : Abrocitinib
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable